Imatinib and Hyperlipidemia
To the Editor: We report on a series of nine patients with hyperlipidemia and either chronic myeloid leukemia or the hypereosinophilic syndrome, in eight of whom plasma lipid levels normalized within one month after imatinib therapy (at a dose of 400 mg daily) was started. All nine patients had hype...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2005-12, Vol.353 (25), p.2722-2723 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2723 |
|---|---|
| container_issue | 25 |
| container_start_page | 2722 |
| container_title | The New England journal of medicine |
| container_volume | 353 |
| creator | Gottardi, Michele Manzato, Enzo Gherlinzoni, Filippo |
| description | To the Editor:
We report on a series of nine patients with hyperlipidemia and either chronic myeloid leukemia or the hypereosinophilic syndrome, in eight of whom plasma lipid levels normalized within one month after imatinib therapy (at a dose of 400 mg daily) was started. All nine patients had hypercholesterolemia (mean plasma total cholesterol level, 254 mg per deciliter; range, 223 to 293); four of them also had hypertriglyceridemia (mean plasma triglyceride level, 264 mg per deciliter; range, 230 to 368). Patients who had concomitant diabetes mellitus, were currently consuming alcohol, or were using oral contraception were excluded. Diet, weight, . . . |
| doi_str_mv | 10.1056/NEJMc052500 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68914666</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68914666</sourcerecordid><originalsourceid>FETCH-LOGICAL-c418t-bab4c4aac9c73d7152ec0e1c0c360a77b965da9d92b8552be126f41bbd282a463</originalsourceid><addsrcrecordid>eNpt0EtLw0AUBeBBFFurK5eCFAU3Ep13MstSqq1U3eh6mFdhSiaJM82i_96EBhTxbu7m43A4AFwi-IAg449vi5dXAxlmEB6BMWKEZJRCfgzGEOIio7kgI3CW0hZ2h6g4BSPESY44pWNwtQpq5yuvp6qy0-W-cbH0jbcueHUOTjaqTO5i-BPw-bT4mC-z9fvzaj5bZ4aiYpdppamhShlhcmJzxLAz0CEDDeFQ5bkWnFklrMC6YAxrhzDfUKS1xQVWlJMJuDvkNrH-al3ayeCTcWWpKle3SfJCIMp5D2_-wG3dxqrrJjEmghCOe3R_QCbWKUW3kU30QcW9RFD2g8lfg3X6eohsdXD2xw4LdeD2AEJIsnLb8G_MN_Dabd4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223933626</pqid></control><display><type>article</type><title>Imatinib and Hyperlipidemia</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Gottardi, Michele ; Manzato, Enzo ; Gherlinzoni, Filippo</creator><creatorcontrib>Gottardi, Michele ; Manzato, Enzo ; Gherlinzoni, Filippo</creatorcontrib><description>To the Editor:
We report on a series of nine patients with hyperlipidemia and either chronic myeloid leukemia or the hypereosinophilic syndrome, in eight of whom plasma lipid levels normalized within one month after imatinib therapy (at a dose of 400 mg daily) was started. All nine patients had hypercholesterolemia (mean plasma total cholesterol level, 254 mg per deciliter; range, 223 to 293); four of them also had hypertriglyceridemia (mean plasma triglyceride level, 264 mg per deciliter; range, 230 to 368). Patients who had concomitant diabetes mellitus, were currently consuming alcohol, or were using oral contraception were excluded. Diet, weight, . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMc052500</identifier><identifier>PMID: 16371644</identifier><identifier>CODEN: NEJMAG</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Benzamides ; Humans ; Hypereosinophilic Syndrome - complications ; Hypereosinophilic Syndrome - drug therapy ; Hyperlipidemias - complications ; Hyperlipidemias - drug therapy ; Imatinib Mesylate ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - complications ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy ; Piperazines - therapeutic use ; Protein-Tyrosine Kinases - antagonists & inhibitors ; Pyrimidines - therapeutic use</subject><ispartof>The New England journal of medicine, 2005-12, Vol.353 (25), p.2722-2723</ispartof><rights>Copyright © 2005 Massachusetts Medical Society. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c418t-bab4c4aac9c73d7152ec0e1c0c360a77b965da9d92b8552be126f41bbd282a463</citedby><cites>FETCH-LOGICAL-c418t-bab4c4aac9c73d7152ec0e1c0c360a77b965da9d92b8552be126f41bbd282a463</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMc052500$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/223933626?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,2759,2760,26103,27924,27925,52382,54064,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16371644$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gottardi, Michele</creatorcontrib><creatorcontrib>Manzato, Enzo</creatorcontrib><creatorcontrib>Gherlinzoni, Filippo</creatorcontrib><title>Imatinib and Hyperlipidemia</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>To the Editor:
We report on a series of nine patients with hyperlipidemia and either chronic myeloid leukemia or the hypereosinophilic syndrome, in eight of whom plasma lipid levels normalized within one month after imatinib therapy (at a dose of 400 mg daily) was started. All nine patients had hypercholesterolemia (mean plasma total cholesterol level, 254 mg per deciliter; range, 223 to 293); four of them also had hypertriglyceridemia (mean plasma triglyceride level, 264 mg per deciliter; range, 230 to 368). Patients who had concomitant diabetes mellitus, were currently consuming alcohol, or were using oral contraception were excluded. Diet, weight, . . .</description><subject>Benzamides</subject><subject>Humans</subject><subject>Hypereosinophilic Syndrome - complications</subject><subject>Hypereosinophilic Syndrome - drug therapy</subject><subject>Hyperlipidemias - complications</subject><subject>Hyperlipidemias - drug therapy</subject><subject>Imatinib Mesylate</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - complications</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</subject><subject>Piperazines - therapeutic use</subject><subject>Protein-Tyrosine Kinases - antagonists & inhibitors</subject><subject>Pyrimidines - therapeutic use</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpt0EtLw0AUBeBBFFurK5eCFAU3Ep13MstSqq1U3eh6mFdhSiaJM82i_96EBhTxbu7m43A4AFwi-IAg449vi5dXAxlmEB6BMWKEZJRCfgzGEOIio7kgI3CW0hZ2h6g4BSPESY44pWNwtQpq5yuvp6qy0-W-cbH0jbcueHUOTjaqTO5i-BPw-bT4mC-z9fvzaj5bZ4aiYpdppamhShlhcmJzxLAz0CEDDeFQ5bkWnFklrMC6YAxrhzDfUKS1xQVWlJMJuDvkNrH-al3ayeCTcWWpKle3SfJCIMp5D2_-wG3dxqrrJjEmghCOe3R_QCbWKUW3kU30QcW9RFD2g8lfg3X6eohsdXD2xw4LdeD2AEJIsnLb8G_MN_Dabd4</recordid><startdate>20051222</startdate><enddate>20051222</enddate><creator>Gottardi, Michele</creator><creator>Manzato, Enzo</creator><creator>Gherlinzoni, Filippo</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20051222</creationdate><title>Imatinib and Hyperlipidemia</title><author>Gottardi, Michele ; Manzato, Enzo ; Gherlinzoni, Filippo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c418t-bab4c4aac9c73d7152ec0e1c0c360a77b965da9d92b8552be126f41bbd282a463</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Benzamides</topic><topic>Humans</topic><topic>Hypereosinophilic Syndrome - complications</topic><topic>Hypereosinophilic Syndrome - drug therapy</topic><topic>Hyperlipidemias - complications</topic><topic>Hyperlipidemias - drug therapy</topic><topic>Imatinib Mesylate</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - complications</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</topic><topic>Piperazines - therapeutic use</topic><topic>Protein-Tyrosine Kinases - antagonists & inhibitors</topic><topic>Pyrimidines - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gottardi, Michele</creatorcontrib><creatorcontrib>Manzato, Enzo</creatorcontrib><creatorcontrib>Gherlinzoni, Filippo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gottardi, Michele</au><au>Manzato, Enzo</au><au>Gherlinzoni, Filippo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Imatinib and Hyperlipidemia</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2005-12-22</date><risdate>2005</risdate><volume>353</volume><issue>25</issue><spage>2722</spage><epage>2723</epage><pages>2722-2723</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><coden>NEJMAG</coden><abstract>To the Editor:
We report on a series of nine patients with hyperlipidemia and either chronic myeloid leukemia or the hypereosinophilic syndrome, in eight of whom plasma lipid levels normalized within one month after imatinib therapy (at a dose of 400 mg daily) was started. All nine patients had hypercholesterolemia (mean plasma total cholesterol level, 254 mg per deciliter; range, 223 to 293); four of them also had hypertriglyceridemia (mean plasma triglyceride level, 264 mg per deciliter; range, 230 to 368). Patients who had concomitant diabetes mellitus, were currently consuming alcohol, or were using oral contraception were excluded. Diet, weight, . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>16371644</pmid><doi>10.1056/NEJMc052500</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2005-12, Vol.353 (25), p.2722-2723 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68914666 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; ProQuest Central UK/Ireland; New England Journal of Medicine |
| subjects | Benzamides Humans Hypereosinophilic Syndrome - complications Hypereosinophilic Syndrome - drug therapy Hyperlipidemias - complications Hyperlipidemias - drug therapy Imatinib Mesylate Leukemia, Myelogenous, Chronic, BCR-ABL Positive - complications Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Piperazines - therapeutic use Protein-Tyrosine Kinases - antagonists & inhibitors Pyrimidines - therapeutic use |
| title | Imatinib and Hyperlipidemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T20%3A09%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Imatinib%20and%20Hyperlipidemia&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Gottardi,%20Michele&rft.date=2005-12-22&rft.volume=353&rft.issue=25&rft.spage=2722&rft.epage=2723&rft.pages=2722-2723&rft.issn=0028-4793&rft.eissn=1533-4406&rft.coden=NEJMAG&rft_id=info:doi/10.1056/NEJMc052500&rft_dat=%3Cproquest_cross%3E68914666%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223933626&rft_id=info:pmid/16371644&rfr_iscdi=true |